αααααβααΎαDBVT β’ NASDAQ
add
DBV Technologies SA - ADR
16.99$
5 ααααΆ, 8:30:00 PM ααααβααα -5 · USD · NASDAQ · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΌααααααααααΆαα
α»ααααααΈαα
α’αΆαααα·α
αα·αααΈαα»α
19.05$
α
αααααααααααα
16.77$ - 18.98$
α
ααααααα½αααααΆαα
α»αααααα
3.30$ - 26.19$
ααΎαβαα»αβααΈααααΆα
686.67Β ααΆα USD
ααα ααα½αααΌαααααα
612.24Β ααΆαα
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
αααα»αβααααααΆαβ
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (USD) | αααααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 2.77Β ααΆα | 158.77% |
α
αααΆαααααα·ααααα·ααΆα | 37.05Β ααΆα | 18.00% |
α
αααΌααα»ααα | -33.16Β ααΆα | -8.94% |
ααααΆααα
αααααα»ααα | -1.20ααΆαα | 57.90% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | -0.21 | 86.19% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | -33.49Β ααΆα | β |
α’ααααΆαααααααααΆαααααα·αααααΆα | β | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (USD) | αααααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 69.84Β ααΆα | 50.38% |
ααααααααα»α | 110.50Β ααΆα | 18.74% |
ααΆαααα½ααα»αααααΌαααα»α | 57.64Β ααΆα | 47.72% |
ααΌαβααααα»α | 52.85Β ααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 168.95Β ααΆα | β |
ααααααααααΉαααααα
| 48.85 | β |
ααα
ααααααΎαααααα | -67.50% | β |
ααα
ααααααΎααΎααα»α | -110.96% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (USD) | αααααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | -33.16Β ααΆα | -8.94% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | -32.44Β ααΆα | -44.43% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -241.00Β ααΆαα | -121.10% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | 130.00Β ααΆαα | 1,757.14% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | -33.37Β ααΆα | -68.79% |
ααα αΌαααΆα
αααααΆααααααα | -21.19Β ααΆα | -62.74% |
α’αααΈ
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
ααΆααααααΎαα‘αΎα
29 ααΈααΆ 2002
αααααβαααααΆα
αα»ααααα·α
117
